Jump to: [Chinese Items]   [0-9]   [ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ] or enter the first few letters:

Showing items 3581-3590 of 12972. (1298 Page(s) Totally) << < 354 355 356 357 358 359 360 361 362 363 > >> View [10|25|50] records per page

Date	Title	Relation
2019-11-27	Discovery of a furanopyrimidine-based epidermal growth factor receptor inhibitor (DBPR112) as a clinical candidate for the treatment of non-small cell lung cancer	Journal of Medicinal Chemistry. 2019 Nov 27;62(22):10108-10123.
2024-06-01	Discovery of a long half-life AURKA inhibitor to treat MYC-amplified solid tumors as a monotherapy and in combination with everolimus	Molecular Cancer Therapeutics. 2024 Jun 01;23(6):766-779.
2021-10-09	Discovery of a metabolic signature predisposing high risk patients with mild cognitive impairment to converting to Alzheimer’s disease	International Journal of Molecular Sciences. 2021 OCt 9;22(20):Article number 10903.
2024-07-17	Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia	Cell Chemical Biology. 2024 Jul 17;Article in Press.
2006-06-15	Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies	Journal of Medicinal Chemistry. 2006 Jun;49(12):3485-3495.
2021-06-16	Discovery of an orally efficacious MYC inhibitor for liver cancer using a GNMT-based high-throughput screening system and structure-activity relationship analysis	Journal of Medicinal Chemistry. 2021 Jun 16;64(13):8992-9009.
2014-10	Discovery of ATR kinase inhibitors from natural products	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1637.
2016-12	Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation	Oncotarget. 2016 Dec;7(52):86239-86256.
2017-04	Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation	Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482.
2021-10-14	Discovery of BPR1R024, an orally active and selective CSF1R inhibitor that exhibits antitumor and immunomodulatory activity in a murine colon tumor model	Journal of Medicinal Chemistry. 2021 Oct 14;64(19):14477-14497.

Showing items 3581-3590 of 12972. (1298 Page(s) Totally) << < 354 355 356 357 358 359 360 361 362 363 > >> View [10|25|50] records per page